Rare Gynecologic Cancers: Advancing Knowledge through Collaboration in Research and Clinical Care

---

LIVE

Tuesday, November 17, 2026, 7:00 AM - Wednesday, November 18, 2026, 1:00 PM, MD Anderson - Duncan Building, Houston, TX


AMA PRA Category 1 Credits™ (11.25 hours), Non-Physician Attendance (11.25 hours)

The 2026 Conference on Rare Gynecologic Tumors is designed for health care professionals involved in the care of patients with rare gynecologic malignancies. The conference provides an intimate, collaborative learning environment that supports in-depth discussion of current evidence, emerging challenges, and evolving clinical strategies in this rapidly advancing field. Through expert-led presentations, case-based discussions, and interactive dialogue, participants will examine recent research findings, novel diagnostic and therapeutic approaches, and best practices for multidisciplinary management of rare gynecologic tumors. This activity aims to enhance clinician knowledge, competence, and clinical decision-making, with the goal of improving patient outcomes and the quality of care for individuals affected by rare gynecologic cancers.

1. Summarize current evidence, emerging research, and evolving clinical guidelines related to the diagnosis and management of rare gynecologic tumors.
2. Analyze complex clinical scenarios involving rare gynecologic malignancies, incorporating pathology, molecular testing, and multidisciplinary considerations into clinical decision-making.
3. Apply individualized, evidence-based diagnostic and treatment strategies for patients with rare gynecologic tumors, including appropriate use of emerging therapies and referral pathways.
4. Incorporate guideline-concordant and multidisciplinary approaches into routine practice to improve consistency, coordination of care, and overall quality of care for patients with rare gynecologic cancers.

The Rare Gynecologic Cancers: Advancing Knowledge through Collaboration in Research and Clinical Care conference will be held on November 17-18, 2026, at UT MD Anderson's Duncan Building (8th Floor), located at 1155 Pressler St., Houston, TX 77030. 

Registration Fees: 

We accept the following forms of payment:

• Credit Cards (MasterCard, VISA, and American Express)

• Check made payable to: The University of Texas MD Anderson Cancer Center (payable through U.S. banks only)

Mail to:

Continuing Professional Education – Unit 1781
The University of Texas MD Anderson Cancer Center
 P.O. Box 301407
 Houston, Texas 77230-1407
Telephone registrations are not accepted

When registering online a receipt (confirmation) will be automatically emailed to the e-mail address you list on the registration form.

Refund/Cancellation Policy: The registration fee, minus a $50.00 administration-handling fee, is refundable if a written request is received on or before Monday, November 6, 2026.  No refunds will be granted after these dates. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of Continuing Professional Education (CPE), reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary.  Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.  In case of activity cancellation, the liability of CPE, is limited to the registration fee.  CPE, will refund the full registration fee. CPE reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. 

For additional information, contact CPE, at 713-792-2223 or toll free at 866-849-5866 or via e-mail: [email protected].

Special Assistance
Contact CPE, at 713-792-2223 or toll free at 866-849-5866 if you have any ADA accommodation needs.

CALL FOR ABSTRACTS

• All abstract submitters should be prepared to present their work as a poster.

• In addition to submitting an abstract, conference registration must be completed.

Abstract Formatting Instructions.

• Limit abstracts to one page, 12-point Times New Roman font, single spaced with one-inch margins, and left justified.

• Abstract Length:  One page only with 325-word limit on US letter size paper.

• Organize the abstract into: Purpose, Methods, Results, and Conclusions.

• All abbreviations or acronyms should be spelled out the first time they are used.

• Provide three to five keywords describing the nature and content of the abstract.

• Please include the name of the conference, title of your presentation, author’s full name, highest degree, and institutional affiliation.

• Also please include the author’s contact number and email address. 

Accepted abstract first authors will be invited to create a Poster of their research for display. Freestanding 4ft. x 8ft. display boards and pushpins will be provided for the poster presentation.  

Abstract and Poster Notification Dates. 

The conference committee will select abstracts for presentations based on the scientific merit and the quality of the content. Abstracts that are not submitted in the format above will not be accepted. Abstracts will not be edited. The deadline for receipt of abstracts is Friday, September 11, 2026, at 11:59 PM CST. The first author of the abstract will receive an automated submission email confirming that the abstract has been received. Notification of acceptance for poster presentations with directives will be sent out via email on Monday, September 21, 2026.   

Submission Guildlines

• Deadline to submit abstracts is Friday September 11, 2026, by 11:59 PM CST

• Abstracts will only be accepted electronically. Submissions should be emailed to: [email protected]

• Authors may submit abstracts of completed work or work in progress within the past two years. Posters that have been presented at other meetings are welcomed.

• Please include with submission: First author’s name/title/credentials, affiliated organization, title of poster, email address, phone number, and collaborators (if any).

• Notifications of acceptance will be email by Monday October 19, 2026.

Important Abstract Dates:

• September 14, 2026 - Abstract Submission Deadline

• September 19, 2026 - Abstract Notification of Acceptance Date

• October 19, 2026 - Acceptance Notification

• November 17-18, 2026 - Conference Date

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 11.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

View the accessibility policy for The University of Texas MD Anderson Cancer Center.

 

Hotel Options: 

Houston Marriott Medical Center
6580 Fannin Street
Houston TX, 77030
713-796-0080
Room Rate:  Varies

Hilton Houston Plaza/Medical Center
6633 Travis Street
Houston TX  77030
713-313-4000
Room Rate:  Varies

DoubleTree by Hilton Houston Medical Center Hotel & Suites
6800 Main Street
Houston, TX  77030
713-528-7744
Rom Rate:  Varies

Hilton Garden Inn Houston Medical Center
6840 Almeda Rd.
Houston, Texas 77030
346-433-8200
Rom Rate:  Varies

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the educational content of a certified continuing education (CE) activity, including faculty, planners, reviewers, are required to disclose all financial relationships with ineligible companies within the prior 24 months. There is no minimum financial threshold. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used on or by patients. All relevant financial relationships have been mitigated prior to the start of the activity.